280P - FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/ HER2- negative metastatic breast cancer patients (MBC) ≤45 years old....

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Cancer in Young Adults
Breast Cancer, Metastatic
Breast Cancer
Presenter BARBARA PISTILLI
Citation Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365
Authors B. PISTILLI1, A. Lardy-Cleaud2, E. JACQUET3, S. Delaloge1, P. Cottu4, M. Debled5, L. Vanlemmens6, M. Leheurteur7, F. Divanon8, A. Gonçalves9, C. Laurent10, B. Coudert11, E. Chamorey12, L. Campion13, M. Mouret-Reynier14, M. Breton15, T. Petit16, G. Simon17, C. Cailliot18, T. Bachelot3
  • 1Breast Cancer, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 2Biostatistics, Centre Leon Bérard, 69008 - Lyon/FR
  • 3Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 4Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 5Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 6Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 7Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 8Pharmacie, CRLCC FRANCOIS BACLESSE, 14076 - CAEN/FR
  • 9Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 10Oncology, INSTIUT DE CANCEROLOGIE DE LORRAINE, NANCY/FR
  • 11Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 12Pharmacy, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 13Biostatistics, Centre Rene Gauducheau, 44800 - Nantes/FR
  • 14Medical Oncology, Centre Jean Perrin, Clermont-Ferrand/FR
  • 15Oncology, CENTRE EUGENE-MARQUIS, RENNES/FR
  • 16Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 17R&d, Unicancer R&D, 75013 - Paris/FR
  • 18R&d, Unicancer R&D, PARIS/FR

Abstract

Background

Metastatic breast cancer (MBC) in young patients (pts) is traditionally considered at poor prognosis. Although current guidelines recommend endocrine therapy (ET) as first line treatment (1st trt) for HR+ HER2- MBC, younger age can lead to more extensive use of first line chemotherapy (CT). In the present analysis, we aimed to assess overall survival (OS) of younger MBC pts compared to older ones, and to explore 1st trt choices in a large real-life multicenter cohort.

Methods

The Epidemiological Strategy and Medical Economics (ESME) Research program aims to collect high-quality real-world data in oncology from 18 French Comprehensive Cancer Centers. Pts who started treatment for a newly diagnosed MBC between Jan 2008 and Dec 2014 were selected in the MBC ESME database. The primary end point of the FICHE-Young study was to compare adjusted OS in pts diagnosed with endocrine-sensitive HR+ HER2- MBC and aged ≤45 vs > 45 at diagnosis. We also evaluated 1st trt choices in both categories and its correlation with OS. Analyses will be adjusted on a propensity score, in order to control selection biases associated with non-randomization.

Results

6265 pts out of 16703 in ESME had HR+/HER2- MBC. Characteristics and 1st trt choices are listed in the Table. Median OS was 62.3 months (mos) (95% CI 56.5-69) in pts ≤45 and 52.8 mos in those >45 (95% CI 50.7-55), p45 yrs oldN8515414Median age40.0 [23;44]63 [45;95]Visceral metastases56.3%51.6%De novo MBC41%42.4%Median time to onset of MBC3.28 yrs [0.50;19.53]9.18 yrs [0.50;43.02]1st trt: ET alone19.4%47.4%Chemo +/- maintenance ET80.6%52.6%

Conclusions

With the limitations of a nonrandomized study population, in this real-world setting, younger HR+MBC pts did not show a poorer prognosis compared to older patients. Many young pts received CT as first line treatment, with no demonstrated benefit over ET alone.

Clinical trial identification

NOT APPLICABLE

Legal entity responsible for the study

UNICANCER

Funding

UNICANCER

Disclosure

All authors have declared no conflicts of interest.